Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Enable Injections and Incyte Forge Partnership to Advance Patient Care in Chronic Blood and Bone Marrow Conditions

Enable Injections and Incyte Forge Partnership to Advance Patient Care in Chronic Blood and Bone Marrow Conditions

Enable Injections, the developer of the enFuse wearable drug delivery system, has entered into a strategic partnership with Incyte Corporation to combine their technologies and improve patient care for certain chronic blood and bone marrow disorders. The collaboration, announced on October 27, 2025, focuses on Incyte's investigational mutant calreticulin selective monoclonal antibody treatment for essential thrombocythemia and myelofibrosis.

NoahAI News10/30/2025
Centene Posts $6.6B Loss Amid Market Challenges, Raises 2025 Outlook

Centene Posts $6.6B Loss Amid Market Challenges, Raises 2025 Outlook

Centene Corporation, a major player in the U.S. healthcare insurance sector, reported a substantial net loss of $6.6 billion for the third quarter of 2025, primarily due to a non-cash goodwill impairment charge of $6.7 billion. Despite this setback, the company has raised its full-year earnings outlook, signaling confidence in its underlying operations and strategy.

NoahAI News10/30/2025
BridgeBio Achieves Milestone in Rare Disease Treatment with Encaleret Success

BridgeBio Achieves Milestone in Rare Disease Treatment with Encaleret Success

BridgeBio Pharma has reported a significant breakthrough in the treatment of a rare endocrine disorder, marking another win for the company's rare disease research portfolio. The experimental drug encaleret has met all primary and key secondary objectives in a late-stage clinical trial for autosomal dominant hypocalcemia Type 1 (ADH1), potentially paving the way for a new treatment standard in this uncommon condition.

NoahAI News10/30/2025
CVS Health Reports Strong Q3 Results, Raises Full-Year Guidance Amid Strategic Shifts

CVS Health Reports Strong Q3 Results, Raises Full-Year Guidance Amid Strategic Shifts

CVS Health Corporation, a leading healthcare company, has reported robust third-quarter results for 2025, surpassing Wall Street expectations and prompting an increase in its full-year earnings forecast. The company's performance reflects significant improvements across its diverse business segments, despite facing challenges in its healthcare delivery unit.

NoahAI News10/30/2025
GSK Abandons CD226 Cancer Therapies, Shifts Focus to ADCs and Other Promising Areas

GSK Abandons CD226 Cancer Therapies, Shifts Focus to ADCs and Other Promising Areas

GSK, one of the world's leading pharmaceutical companies, has announced a significant shift in its oncology strategy, abandoning its once-promising CD226 axis cancer therapies and refocusing efforts on other areas with high potential, including antibody-drug conjugates (ADCs).

NoahAI News10/30/2025
Genentech Announces Third Round of Layoffs in 2025, Affecting 118 Employees

Genentech Announces Third Round of Layoffs in 2025, Affecting 118 Employees

Genentech, a subsidiary of Roche, has announced its third round of layoffs this year at its Bay Area headquarters. The latest workforce reduction, affecting 118 employees across multiple departments, highlights ongoing restructuring efforts within the pharmaceutical giant.

NoahAI News10/30/2025
Teladoc Health Reports Revenue Decline, Shifts Focus to AI-Driven Solutions

Teladoc Health Reports Revenue Decline, Shifts Focus to AI-Driven Solutions

Teladoc Health, a leading telehealth provider, has reported a 2% year-over-year decline in revenue for the third quarter of 2025, signaling ongoing challenges in the virtual care market. Despite this setback, the company is actively pursuing artificial intelligence (AI) initiatives to enhance its service offerings and improve operational efficiency.

NoahAI News10/30/2025
Alnylam's Amvuttra Continues Strong Performance in ATTR Market

Alnylam's Amvuttra Continues Strong Performance in ATTR Market

Alnylam Pharmaceuticals' rare disease drug Amvuttra has once again exceeded Wall Street expectations, demonstrating robust growth in the third quarter of 2025. The company's transthyretin (TTR) franchise, led by Amvuttra, has prompted Alnylam to raise its full-year sales guidance, reflecting the drug's successful expansion into the transthyretin amyloid cardiomyopathy (ATTR-CM) market.

NoahAI News10/30/2025
M&A Activity Heats Up in Pharmaceutical Industry as Mid-Cap Companies Look to Bolster Pipelines

M&A Activity Heats Up in Pharmaceutical Industry as Mid-Cap Companies Look to Bolster Pipelines

In a landscape typically dominated by Big Pharma deals, a new wave of mergers and acquisitions is emerging from small- to mid-cap pharmaceutical companies. These firms, with annual revenues ranging from $2 billion to $25 billion, are increasingly looking to strengthen their pipelines through strategic buyouts and partnerships.

NoahAI News10/30/2025
Nvidia Deepens Presence in Life Sciences with Strategic Partnerships

Nvidia Deepens Presence in Life Sciences with Strategic Partnerships

Nvidia, the technology giant known for its graphics processing units and artificial intelligence solutions, is making significant inroads into the life sciences sector through a series of strategic partnerships. Recent collaborations with Johnson & Johnson's medical technology unit, Verily, and Eli Lilly underscore Nvidia's commitment to revolutionizing healthcare and pharmaceutical research.

NoahAI News10/30/2025
Parents Struggle with Fragmented Pediatric Care, Survey Reveals

Parents Struggle with Fragmented Pediatric Care, Survey Reveals

A recent survey conducted by Zarminali Pediatrics has shed light on the challenges parents face when navigating pediatric and specialty care for their children. The study, which included 405 parents with private health insurance, reveals significant gaps in communication, coordination, and technology use within the pediatric healthcare system.

NoahAI News10/30/2025
AbbVie Halts Development of Dragonfly Cancer Asset, Reaffirms Commitment to c-Met Therapies

AbbVie Halts Development of Dragonfly Cancer Asset, Reaffirms Commitment to c-Met Therapies

AbbVie has announced the termination of clinical activities surrounding ABBV-303, a natural killer (NK) cell engager developed in collaboration with Dragonfly Therapeutics. The decision to halt the phase 1 solid tumor trial was attributed to "strategic considerations," according to the federal trial database clinicaltrials.gov.

NoahAI News10/30/2025
«1...131415...67»